Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"
- PMID: 31802399
- DOI: 10.1007/s40262-019-00849-y
Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"
Comment in
-
Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".Clin Pharmacokinet. 2020 Feb;59(2):277-279. doi: 10.1007/s40262-019-00851-4. Clin Pharmacokinet. 2020. PMID: 31802398 Free PMC article. No abstract available.
Comment on
-
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?Clin Pharmacokinet. 2020 Jan;59(1):1-5. doi: 10.1007/s40262-019-00812-x. Clin Pharmacokinet. 2020. PMID: 31432471 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
